Abstract library

289 results for "psychosocial symptoms".
#2049 Identifying the Severity of Psychosocial Symptoms among Patients Diagnosed with Pancreatic Neuroendocrine Tumor. Do We Really Need Emotional Support Groups?
Introduction: Neuroendocrine tumors (pNETs) are the second most common neoplasm. Most of the pNETs are diagnosed at later stages among those patients who are underprivileged. The diagnosis and treatment of neuroendocrine tumor is a continuous emotional distress for both patient and their family.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zai S S A
#2701 Assessing the Gaps in Experience and Knowledge of Australian Primary Health Care Professionals (GPs), in Treating and Caring for the Increasing Number of Australian Neuroendocrine Tumour (NET) Patients
Introduction: Conservatively,the incidence of NETs is 7 / 000' p.a, however,the prevalence of patients living with NETs is higher,40/000',making it the 2nd most common GI malignancy after colorectal cancer.Patients are living longer,however,with impaired quality of life.Management of debilitating symptoms such as diarrhoea,fatigue,anxiety,and flushing are complex and heterogenous.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Simone Leyden
#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results
Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: RN Gladys Grance
#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye
#1470 Exploring Gastrointestinal Symptoms And Their Impact on Quality of Life in Patients with Neuroendocrine Tumours
Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
Authors: Williams M, Reid K, Ng S, Benny A, ...
#2130 Remote Tracking of Symptoms, QoL and Wellbeing within the New Wales NET Service
Introduction: Patients with NETs have worse health-related quality of life (HRQoL) than the general population.
Technological advances have significantly increased electronic patient-reported outcome (ePRO) data collection capabilities.
There is little longitudinal PRO/ePRO data and limited data on gastrointestinal symptoms, particularly ‘diarrhoea’, in NET patients.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Mark Reynolds
#2039 Short-Term Change in Symptoms and Adverse Events Evaluation after PRRT – First Experience after 56 Patients
Introduction: From March 2016, patients with M+ NET are treated with PRRT at the Netherlands Cancer Institute.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MSc Daphne Huizing
#2067 Recognition of Primary Neuroendocrine Tumors - A Challenge
Introduction: Neuro endocrine tumors of liver are rare.Most of the neuroendocrine tumors of the liver arise from gastrointestinal tract, especially from appendix.ileum and pancreas.Primary hepatic neuro endocrine tumors is a rare clinical entity, requiring strict exclusion of possible extra-hepatic primary sites for its diagnosis.Most challenging in diagnosis is diversity in presentation of primary symptoms.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Doctor Azka Athar
Authors: Athar A, ...
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster
#2179 Exploring Nutrition Screening and Management Practices amongst Health Professionals Managing Patients with Neuroendocrine Tumors
Introduction: Patient’s with neuroendocrine tumours (NET) are at nutritional risk due to symptoms and side-effects of treatment. Current evidence based guidelines lack information regarding optimal nutritional management and supportive care.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Erin Kennedy
Authors: Kennedy E, Kiss N, Michael M, Gough K, ...